Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GUCY1B2 | O75343 | 2/20 | 0.30 |
| ▸ | GUCY1A2 | P33402 | 2/20 | 0.30 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.30 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6338357 | 0.79 | GABRA1 (0.40) | RXFP1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6350431 | 0.77 | RXFP1 (0.44) | RXFP1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7479574 | 0.77 | RXFP1 (0.56) | RXFP1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4760356 | 0.73 | L3MBTL1 (0.54) | RXFP1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6339680 | 0.72 | GABRA1 (0.39) | — | |
| SCHEMBL5527076 | 0.61 | L3MBTL1 (0.58) | RXFP1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18973416 | 0.57 | GABRG2 (0.43) | MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL3082762 | 0.57 | NPC1 (0.42) | — | |
| SCHEMBL29840696 | 0.57 | IDO1 (0.46) | MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2123489 | 0.57 | IDO1 (0.46) | MEN1KMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949549-B2 | Imidazolophthalazine derivatives as ligands for GABAA receptors | MERCK SHARP & DOHME LTD. (GB) | 2005-09-27 | — | — | US | disclosed |
| US-20040147517-A1 | Imidazolophthalazine derivatives as ligands for gabaa receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-07-29 | — | — | US | disclosed |
| EP-1303516-A1 | IMIDAZOLOPHTHALAZINE DERIVATIVES AS LIGANDS FOR GABA A? RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002006285-A1 | IMIDAZOLOPHTHALAZINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147517-A1 | Imidazolophthalazine derivatives as ligands for gabaa receptors | GABRA5, GABRP, GABRA6 | RXFP1 1596/4885L3MBTL1 4690/4885MEN1 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.